Vaccines for preventing anthrax

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Donegan, Sarah ^a   Bellamy, R ^b   Gamble, C ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; PLACEBO;

ANTHRAX; CLINICAL TRIAL; COCHRANE LIBRARY; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFECT; DRUG EFFICACY; EMBASE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFORMATION RETRIEVAL; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 44949247373     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006403     Document Type: Review

References (20)

1. CDC 2006a Centers for Disease Control and Prevention. What is the anthrax vaccine?. www.cdc.gov/ncidod/dbmd/diseaseinfo/anthrax_g.htm#whatisvacc (accessed 9 March 2006).
2. CDC 2006b Centers for Disease Control and Prevention. CDC Anthrax Vaccine Clinical Trial. www.clinicaltrials.gov/ct/show/NCT00119067 (accessed 9 March 2006).
3. Dixon 1999 Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. New England Journal of Medicine 1999;341(11):815-26.
4. FDA 2004 Food, Drug Administration. Biological products; bacterial vaccines and toxoids; Implementation of efficacy review. www.fda.gov/OHRMS/ DOCKETS/98fr/80n-0208-nfr0001.pdf 5 January 2004 (accessed 9 March 2006).
5. Gorse 2006 Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, et al.Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine 2006;24(33-4):5950-9.
6. Higgins 2005 Higgins J, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 September 2006).
7. Inglesby 2002 Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al.Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287(17):2236-52.
8. Jernigan 2002 Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, et al.Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerging Infectious Diseases 2002; Vol. 8, issue 10:1019-28.
9. Joellenbeck 2002 Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, editors. Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-Up Agency. The anthrax vaccine, Is it safe? Does it work?. Washington, DC: The National Academies Press, 2002.
10. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
11. Mahan 2004 Mahan CM, Kang HK, Dalager NA, Heller JM. Anthrax vaccination and self-reported symptoms, functional status, and medical conditions in the National Health Survey of Gulf War Era Veterans and Their Families. Annals of Epidemiology 2004;14(2):81-8.
12. Payne 2006 Payne DC, Rose CE Jr, Kerrison J, Aranas A, Duderstadt S, McNeil MM. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. Archives of Neurology 2006;63(6):871-5.
13. Pitt 2001 Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al.In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 2001;19(32):4768-73.
14. Reuveny 2001 Reuveny S, White MD, Adar YY, Kafri Y, Altboum Z, Gozes Y, et al.Search for correlates of protective immunity conferred by anthrax vaccine. Infection and Immunity 2001;69(5):2888-93.
15. Review Manager 4.2 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
16. Salisbury 1996 Anthrax. In: SalisburyDM, BeggNT editor(s). Immunisation against infectious disease. London: HMSO, 1996:61-3.
17. Sever 2004 Sever JL, Brenner A, Gale AD, Lyle JM, Moulton LH, Ward BJ, et al.Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiology and Drug Safety 2004;13(12):825-40.
18. Turnbull 1991 Turnbull PC. Anthrax vaccines: past, present and future. Vaccine 1991;9(8):533-9.
19. VaxGen 2005 VaxGen. Anthrax vaccine candidate. www.vaxgen.com/products/index.html (accessed February 2005).
20. Jefferson 1998 Jefferson T, Demicheli V, Deeks J, Graves P, Pratt M, Rivetti D. Vaccines for preventing anthrax. Cochrane Database of Systematic Reviews 1998, Issue 1.Art. No.: CD000975. DOI: 10.1002/14651858.CD000975.pub2.